And what portion of your capacities, your dedicated capacity will be utilized for these seven molecules? JUBLINGREA 399.05 0.16 % (+0.65) Place Order How to use scorecard? Add, track and import stocks to your Absolutely. Sorry to interupt you sir. Thank you. Or are the product already developed so that you only have to market it once they are the capacities are ready? If we try to understand it, like we are as and when we are able to get the coal cost under our control, will be back to 20% plus margins, and we are at a base of, lets say, INR1,500 crores kind of top line. Let me now take you through the financial and operational performance of Jubilant Ingrevia Limited for the third-quarter of this financial year. I think on a 64-page PowerPoint presentation, we should have every time why somebody should ask, what is the volume growth quarter-on-quarter or year-on-year. BSE: 543271, 402.85 The products which we talked about is still under development and scale-up. First question is the quality of Diketene, their capacity utilization. So sometime in some quarter you have the product mix, which gives you a little bit of lower revenue, but that doesnt mean that our volume has not grown. Thank you. I think you must appreciate the kind of declaration we give as Jubilant Ingrevia is much more than anyone else. These plants will start giving benefits in a phased manner. Sir, the last question in the Nutrition segment, have you changed any capex because now we are looking at cosmetics grades with [phonetic] vitamin B3 as well, which was not there before. Is this something new that we have announced? That is power and fuel, correct? As you can see that the volume growth has come clearly from the specialty chemical business and in nutrition business we have informed you that there is a de-growth in volume, both year-on-year, as well as quarter-on-quarter. Every investment we are making, once it comes on ground, we give a return of asset investment to the close to two plus. Certainly correct. But as of now, our major volumes are domestic. Interestingly, 2020 AlphaStreet Inc. All Rights Reserved, Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript, All you need to know about Antony Waste Handling Cell in one article, Demystifying the Leading Non-Ferrous Recycling Company of India. Thank you once again for your interest in Jubilant Ingrevia. So you are right. So can we sort of draw a communication to the investors and potential investors, where we keep them updated on a regular basis, maybe a monthly basis or something, where we update them about the situation, current situations? So that is on track. On the call today, we have Mr. Shyam Bhartia - Chairman, Mr. Hari Bhartia - Co- But unfortunately, because of the lower demand, we were not in a potion to utilize the plant. Thats it from me. [Operator Instructions] Please note that this conference is being recorded. The products are clear from R&D. One, if I look at your Specialty Chemicals business and assume the COGS to be only raw materials and power and fuel, basically, what would be the ratio between raw material and power and fuel in your COGS for Specialty Chemicals only [Indecipherable]. Now as you know that we are generating our own power in Gajraula, and we plan to generate our own power in Bharuch. But what would be the capacity utilization there on ethyl acetate? And this is something which is known to everybody because we are not the only sufferer of FSA. So maybe in FY 2024, we will have certain portion. So will it be possible for you to tell us what contribution within the Specialty Chemicals is driven by the CDMO business currently? Rest all, the business is really standing very strong, as you can see with the results. So what is your current inventory deal? We are pleased to inform that our specialty chemical business, revenue grew by 34% year-on year. We are trying to recover the cost increase from our customer from the products we can recover our costs so I dont say I dont make any commitments on the margins that it will not improve because it will all depend that, if we can realize better pricing in our product, we can meet our all the volumes projections, probably we should be improving, why not. So what is the visibility on the revenue side, will be really helpful? So now we have earmarked Diketene, where we are targeting 100% utilization probably by the end of this financial year, then we have two projects in the CDMO and the multiple purpose CDMO which are going to go operational. Hi, good evening, sir. So basically if you see that there is a sequential increase in the Specialty Chemicals EBITDA and the margins have come up to 18.6%. Sir, how I mean, in terms of your ability to pass on the cost push that youre seeing in power and fuel. So 6% to 7% from here, when we are talking about increasing contribution from the Specialty Chemicals business. Yes. So when I say it will be in line with last three quarters. On your question on Chemical Intermediates, as I stated, acetic anhydride, our volumes are growing. And sir, two quick questions is your 2 CGMP plants. For the fourth quarter, the company reported sales was INR 11,294.8 million compared to INR 12,758.7 million a year ago. I would now like to hand the conference over to Mr. Prakash Bisht for closing comments. So, my first question is on the Specialty Chemicals. more, View news and calendar events of your holdings, Manage your watchlists. [Operator Instructions] The next question is from the line of Siddharth Rangnekar from Equirus Securities. Investors Presentation Investors Investors Presentation Click to download a PDF below. And this is no 10% to 15% of the cost of the product, not on revenue part. So you are very right. Finance cost during the quarter was at INR5.1 crores versus INR7.16 crores in FY 2022 on account of repayment of high-cost long-term loans and lower average utilization of debt. Thank you very much. Similarly, revenue from operations during nine months FY23 was at INR3,628 crores as compared with INR3,654 crores during the same period last year witnessing a marginal de-growth of 1% on year-on-year basis. One is the overall price increase of coal. Thank you. Markets Today Top Gainers Top Losers Discover Search all filings. Sir, thanks for the opportunity. So just wanted to get your sense also in terms of the visibility for the ramp-up of these capacities. We use cookies to recognize your repeat visits and preferences, as well as to measure We are utilizing the existing capacity with some debottlenecking, et cetera. And also, if you can give us further breakdown of importation in Specialty Chemicals, you are going to consider 50% of your revenue at that time. Same is the situation for agro chemicals, same is the situation for any other end use of anhydride. So this is absolutely unlikely that we will not get FSA coal. So please dont just calculate in mathematics and [indecipherable]. And sir, my last question to Rajesh, sir, basically what were talking about is well be improving our Specialty Chemical and Nutritional business to 65% over the next three, four years, and that will give us far better margin and very respectable ROE and ROCE. Good evening, everyone. So other expenses includes all the rest of the expenses because the way the SEBI format has been designed, you have to show material separately, employee costs separately. And sir, what would be the reason behind the lower demand for ethyl acetate? Copyright 2023 Surperformance. So if you see the revenue side visibility, its very clear, as we have been saying every time that whatever we are making investment. Jubilant Ingrevia Ltd. investor presentations, annual reports, calls But at the same time, you are very right, we are in full control and we have plans to improve efficiencies all over, and this is a continuous exercise. : +91-5924-267437, Scan the QR code to Nutritional business revenue de-grew by 36% on account of lower demand owing to post flu impact and excess inventory situation across the value chain, coupled with the short-term demand impact in Europe due to ongoing geopolitical situation. watchlists, Keep track of your watchlist stocks - news, latest corporate So this we have built up to make value-added products, which I have been talking all the time. The net working capital percentage and number of days of working capital for Q2 FY 2023 on the basis of trailing 12 months turnover was at 17.9% and 65 days, respectively. Volume, very clearly, I told you as much investments are coming, those volumes will be in three to four weeks three to four quarters will be utilized. So all that is going to increase our expenses. So its ongoing. Specifically on our Specialty side, what we have been talking is turning out to be the reality, which will continue. And given the crisis that were witnessing there, therefore a potential for you to probably garner more market share? As I said, in coal cost, it is a marginal improvement. Overall revenue grew by 7% year-on-year basis, mainly on account of higher sales performance by Specialty Chemicals business. So from where we are seeing, Im sure youre also seeing the same angle, what we have said[Phonetic] for FY27 is still standing through, and all the investments which we have planned has no change. On Chemical Intermediates segment, our volumes have grown by almost 10% to 12 %, 10% by volume growth. So therefore, it is very short term. Yes. Investor Presentation 2022-23 Click to download a PDF below. So how much would that INR40 crores compare in the current quarter? So thats about 15%. This transcript is produced by AlphaStreet, Inc. So there are clear-cut core initiatives in business we have planned. The next question is from the line of Nitesh Dhoot from Prabhudas Lilladher. Thank you. So they are not sitting idle. Revenue was INR 48,060.6 million compared to INR 49,808.5 million a year ago. Jubilant Ingrevia Limited Recommends Final Dividend for the Year Ended March 31 2023, Jubilant Ingrevia Raises INR500 Million Via Issue of Commercial Papers, Jubilant Ingrevia Raises INR500 Million From Issue of Commercial Papers, Jubilant Ingrevia Commissions New Acetic Anhydride Plant at Bharuch, India, Co-Chief Executive Officer, Director & MD. Sure sir, thanks a lot for the detailed reply. The next question is from the line of Dhruv Muchhala from HDFC Mutual Funds. In Chemical Intermediates business the revenue on year-on-year is impacted due to lower prices of feedstock Acetic acid meeting to lower sales prices of Acetic Anhydride and Ethyl Acetate. We have also prepared detailed plan and initiatives, including digital implementations to optimize coal consumption through efficiency improvement in consumption as well as in generation. So as I said, as soon as the capacities come, we will utilize the volume. Similarly, EBITDA for H1 FY 2023 was at INR311 crores as compared with INR490 crores during H1 FY 2022. And sir, just last on my side, on vitamin B3 and the business which has been impacted because of the flu. On your second question on CDMO, there is continuous working to improve our pipeline. Jubilant Ingrevia Limited Reports Earnings Results for the Fourth Quarter and Full Year.. So earlier, it used to be around 8%, 8.5%. So that time, if you give that revenue keep adding. So overall, five to six months it takes. What we are we are not in a position to recover 100% is the difference of FSA versus the normal coal. But thats not a strategic purchase. First, if you can share, sir, I mean, you shared the volume numbers of Specialty, but for the Health & Nutrition and Intermediate if you can share that, please? I think it is in the range of about 12 % to 14%. The next question is from the line of Romil Jain from Electrum PFS. In Nutrition & Health Solutions business flu situation in US and Europe is normalizing. Now that FSA coal, as I explained in the last question also, we are very sure that the situation has to come to normal definitely by Q4 of this year. Hello. Net-debt was at INR352 crores at the end of Q3 FY23 and blended interest-rate as on December 31, 2022, was 7.03%. We are still just in single digits of percentage which we can take from China. Yeah, hi sir, good evening and thanks for the opportunity. Net income was INR 3,075 million compared to INR 4,767.1 million a year ago. So actually, other than the Nutrition business in overall business the volume consistently is growing in Specialty Chemical as well as in Acetic Anhydride and since Nutrition business, Niacinamide situation has not improved. I think we should follow because every now and then, Im observing that people are asking about volume growth and we are not able to provide those [indecipherable]. One is that we have taken two products as a strategic decision to improve inventory to gain in market share and profitability in next two quarters. Thank you. So four questions from my side. The company has strong plans to significantly reduce overall energy costs in a phased manner initiatives such as sourcing power from grid and renewable resources. So as we will catch up the volume, you will see the overall profitability of Chemical Intermediates business improving, which is happening. Similarly, PAT for H1 FY 2022 was at INR164 crores as against INR2 79 crores PAT in H1 FY 2021. Our new GMP and non-GMP facilities projects are slightly delayed by couple of months and are expected to be commissioned in next two months time-frame. We are keeping a very close watch on the demand and take a decision promptly to add capacity. We hope we have been able to answer your queries. NSE: JUBLINGREA Right now, it will be in the range of 15% to 18%. So for time being, for a few months, probably well go for short-term borrowing. Interestingly, 2020 AlphaStreet Inc. All Rights Reserved, Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript, All you need to know about Antony Waste Handling Cell in one article, Demystifying the Leading Non-Ferrous Recycling Company of India. So this Specialty Chemicals definitely includes Diketene business also. Just [technical issue]. announcements and more, Your customized notes, created parameters and more, Set live portfolio/watchlist alerts and view recent alerts, Manage and view recently triggered price alerts, DVM - High Performing, Highly Durable Companies, Copyright 2023 Giskard Datatech Pvt Ltd, Nifty50 companies average YoY revenue changed by 13.79%, Results Declared in Last Two Days with both YoY and QoQ Profit Growth, MFs for your child's education or retirement, Technical Stock Screeners (RSI, MFI, EMA/SMA and more), Trending Today: Stocks with Highest Dividend Yields, Just getting started? Some of the plants are lower. So the niacinamide volumes are also lower, even realization is also lower, of course, because the inventories are high. In fact, the coal is available, government is also working very, very aggressively to make the rail available for the industry. So if 30% capacity is utilized, you can assume what is the revenue we are generating. I now invite Mr. Shyam Bhartia to share his comments please. Help us with your details and we will get back to you, 1A, Sector 16A, Noida - 201 301, While we continue to leverage our capacity from existing as well as newly built plant and our upcoming Acetic Anhydride plant at Bharuch is nearing completion and is expected to be ready during Q4 FY23. We are not in a position to grow volume. Nutrition business and Nutrition & Health Solutions business. Obviously, the absolute EBITDA is growing, but you dont see the full impact because of this impact of FSA. Yes, yes. And lastly, we have continuously introducing new products in pyridine, pyridine derivatives, which also because we are expanding non-GMP facilities. So just to be rest assured that as soon as the capacity comes in few quarters, the capacities are really utilized to an optimum level. Secondly, I just explained that we are adding a new capital plan for nutraceutical vitamin B4 for food business, you can see about INR100 crore increase in nutraceutical segment and debottlenecking. And one of the industry, which is die industry and packing industry is also not doing as great as it should be doing, which also is expected to normalize Q4 or Q1 next year. So please follow one practice that is my request. So that is on track and we are servicing it on time. But in the next couple of quarters, the volume situation is definitely showing us that the utilization is going to significantly improve. So it depends on the price. Thank you. So nobody gets, its not only we. Pratik, so other expenses, the way the SEBI format is so it is not all fixed expenses. While we expect the coal supply to normalize soon, we also continue to explore alternative energy solutions for future. We are also glad to share that the Board has been recommended interim dividend of 250% that is 2.50 per equity share of the face value of INR1 each but the FY2023. How good are your current hold decisions? Honestly speaking, as we just explained to you in the last question, the Diketene business right now is not generating significant revenue. NSE+BSE Volume, NSE alerts, Analyse your portfolio - Concentration analysis, Portfolio NAV and What I said that we are making alternate adjustment is not to the extent of FSA, we said we will be definitely working on the energy cost reduction overall. And on a different side, if we discuss, I can even talk to you what kind of volume growth we are talking. We continue our efforts towards improving our revenue mix of Specialty and Nutrition segment to 65% by FY 2020 from 46% in FY 2022, and we believe this to be a key driver for overall margin improvements. So that will be a normal situation, we will achieve in a normal FSA availability. But our volumes have increased, it is just that prices of Chemical Intermediate segment has come down, that is why you see the revenue at the same level. We have told you that we have already started selling the Diketene. So we have a huge opportunity for increasing our volumes in Europe. Sir, if I understand this correctly, the power and fuel costs, which has increased any 15%, 16% of sales. The capital expenditure during the quarter was approximately INR110 crores. So volume of business has already increased. We will move to the next question from the line of Rahul Veera from Abakkus Asset Manager. Demand continued to be remained impacted also due to geopolitical situation in Europe and severe COVID restrictions in China. If you can speak in the handset mode, please. Hope, I have answered all your three questions. That number has changed now. So net debt has increased to INR2 80 crores. But of late, we are also seeing a positive trend of ethyl acetate as well. However, your specific question, I think currently, we are utilizing our facility to the tune of 40% to 50%. You can see our overall Chemical Intermediates performance of two years before and now has significantly improved, and this will continue to improve because we are going to utilize this plant fully as well as this Q4, we will get the additional plant. This domestic procurement is very small volume, and that happens on the spot availability situation. announcements and more, Your customized notes, created parameters and more, Set live portfolio/watchlist alerts and view recent alerts, Manage and view recently triggered price alerts, DVM - High Performing, Highly Durable Companies, Copyright 2023 Giskard Datatech Pvt Ltd, Nifty50 companies average YoY revenue changed by 13.79%, Results Declared in Last Two Days with both YoY and QoQ Profit Growth, MFs for your child's education or retirement, Technical Stock Screeners (RSI, MFI, EMA/SMA and more), Trending Today: Stocks with Highest Dividend Yields, Just getting started? And secondly, in India, the demand in packaging industry is down. Basic earnings per share from continuing operations was INR 3.29 compared to INR 4.31 a year ago. So this increase is across let me explain you. No, this is rupee. With this, I now hand over to Rajesh to discuss about the business in detail. The second impact on that percentage is our FSA coal. We have 50% to 60% market share, but there are other products, where we are capturing more market share because I said because of China plus situation now, globally. We continue to observe a positive traction of demand for our other specialty chemicals from both domestic as well as international customers. And will it be effective from current quarter or next quarter? Nutrition business revenue was at INR114 crores during the quarter. Next question is from the line of Rohan Gupta from Naama. So India is capturing more and more market share in global market. I think we are planning to utilize to 70% to 75% of capacity. 1 O 0 T 4,923.5 Operating Revenue TTM Cr High in industry 323.8 Net profit TTM Cr High in industry 6.6 Net Profit Margin TTM % Below industry Median 13.5 Revenue Growth (TTM) Below industry Median -30 Profit Growth (TTM) Negative Net Profit TTM Growth % Jubilant Ingrevia Ltd. investor presentations, annual reports, calls Competitors/Peers
House For Rent In West Hills, Dr Elsey's Cat Attract Litter, Duplex For Sale In Keizer Oregon, Articles J